The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved Thursday by the FDA for previously treated patients with multiple myeloma. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback